DermTech’s Collaborators Present Research Studies at AAD Supporting the Use of “Adhesive Patch Skin Biopsy” in Cutaneous Basal Cell and Squamous CellCarcinoma

Second research abstract presented highlights the cost savings of using DermTech’s Pigmented Lesion Assay versus traditional visual assessment and histopathology on lesions suspicious of melanoma

SAN DIEGO--()--DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today the presentation of two studies at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego. The studies highlight DermTech’s focus on expanding applications for their platform technology into other dermatologic conditions as well as their continued focus on improving patient care and reducing costs.

“Clinical and Economic Implications of a Noninvasive Molecular Pathology Assay for Early Detection of Melanoma”

James Sligh, MD, PhD, Division Chief of Dermatology at The University of Arizona Cancer Center, presented a poster entitled, “A Non-Invasive Gene Expression Assay for Cutaneous Basal Cell and Squamous Cell Carcinoma.” The data demonstrated the ability of non-invasive gene expression testing to differentiate primary cutaneous basal cell and squamous cell carcinoma samples from benign and other precursor lesions (e.g. actinic keratosis). The novel multi-target gene panel successfully differentiated these lesions with both a high sensitivity of 91% (95% Cl 86%-95%) and specificity of 87% (95% Cl 80%-92%).

The second research study entitled, “Clinical and Economic Implications of a Noninvasive Molecular Pathology Assay for Early Detection of Melanoma,” highlighted the cost savings of the Pigmented Lesion Assay (PLA) use on lesions suspicious of melanoma versus visual assessment and histopathology (VAH). The higher accuracy of the PLA use versus VAH resulted in fewer unnecessary procedures and office visits, while not compromising melanoma detection.

“The potential effects of integrating this non-invasive test into dermatology practice include possible reduced direct medical costs and improved patient care and experience,” said co-author Darrell Rigel, MD, Clinical Professor of Dermatology at New York University Medical Center.

About DermTech

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. DermTech is headquartered in San Diego. For additional information visit dermtech.com.

Contacts

Company Contact:
DermTech, Inc.
Sarah Dion, MBA
VP, Sales and Marketing
(858) 450-4222
sdion@dermtech.com
or
Media Contact:
Little Dog Communications Inc.
Jessica Yingling, Ph.D.
(858) 344-8091
jessica@litldog.com

Recent Stories

RSS feed for DermTech, Inc.

Release Summary

DermTech Presents Research at AAD Supporting Use of “Adhesive Patch Skin Biopsy” in Basal and Squamous Cell Carcinomas and on Health Economics of PLA

DermTech, Inc.